Colgate-Palmolive
NYSE: CL
Colgate-Palmolive (CL) is a global consumer products company that sells oral care, personal care, home cleaning products and pet nutrition. Its Oral Care business, led by Colgate toothpaste and toothbrushes, is a major focus for analysts, alongside its Hill’s Pet Nutrition business, which sells specialized food for dogs and cats.
- Sector
- Consumer Non-Durables
- Industry
- Household/Personal Care
- Employees
- 33,600
- Founded
- 1806
- Website
- colgatepalmolive.com ↗
The forecast figures are tipranks’s, read on 2026-10-27 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-05 and linked below.
Colgate-Palmolive forecast
The forecast in short
tipranks records 12 analyst ratings on Colgate-Palmolive and summarises them as “Moderate Buy”. Their average 12-month price target is 98.33 (Potential Growth = 5.62%). Its tipranks score is 7 out of 10 — Neutral. These are tipranks’s figures as read on 2026-10-27, not CariBroker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 78.58 B
≈ RM 321.43 B
Share price
USD 98.85
≈ RM 404.36 · 18 Nov close
#333World ranking
tipranks score
Neutral
Analyst ratings
Moderate Buy
- Buy867%
- Hold433%
- Sell00%
tipranks’s own summary of the 12 ratings above.
12 months price forecast
98.33 Potential Growth = 5.62%
As tipranks publishes it. CariBroker has not recalculated any of it.
Financials
Q3 earnings, quarter ending Sep 29, 2026
| Measure | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | 5.37B | 2.66% up |
| Net income | 751.00M | 2,129.73% up |
| Earnings per share | 0.94 | 3.52% up |
| Net profit margin | 13.99% | 2.35% down |
| Free cash flow | 1.04B | 18.73% down |
| Debt-to-equity ratio | 26.79 | 172.40% up |
Revenue and net income, last 4 quarters
Total revenueNet income
Analyst profiles: who made each call, and when
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Andrea Faria Teixeira | J.P. Morgan | Buy | USD 104 | 2026-10-19 |
| Lauren Lieberman | Barclays | Hold | USD 87 | 2026-10-16 |
| Peter Grom | UBS | Buy | USD 106 | 2026-10-15 |
| Peter Galbo | Bank of America Securities | Buy | USD 100 | 2026-10-09 |
| Nik Modi | RBC Capital | Buy | USD 104 | 2026-10-06 |
Show all 18
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Christopher Carey | Wells Fargo | Hold | USD 90 | 2026-10-05 |
| Bonnie Herzog | Goldman Sachs | Buy | USD 100 | 2026-10-05 |
| Michael Lavery | Piper Sandler | Buy | USD 95 | 2026-09-21 |
| Unknown Analyst | Bernstein | Hold | USD 99 | 2026-09-15 |
| Robert Moskow | TD Cowen | Hold | USD 90 | 2026-08-03 |
| Stephen Powers | Deutsche Bank | Buy | USD 101 | 2026-08-03 |
| Dara Mohsenian | Morgan Stanley | Buy | USD 104 | 2026-08-03 |
| Filippo Falorni | Citi | Buy | USD 110 | 2026-07-14 |
| Taylor Conrad | Argus Research | Hold | N/A | 2026-06-09 |
| Robert Ottenstein | Evercore ISI | Buy | USD 100 | 2026-06-08 |
| Andy Sim | DBS | Hold | USD 95 | 2026-05-03 |
| Kaumil Gajrawala | Jefferies | Hold | USD 88 | 2026-04-21 |
| Edward Lewis | Rothschild & Co Redburn | Buy | USD 100 | 2026-04-21 |
Investment strengths
Free Cash Flow Generation
Consistent, large free cash flow (TTM ~$3.86B) funds dividends, buybacks and debt service, enabling durable capital allocation. Strong operating cash flow (~$4.46B) supports investment in brands, innovation and working capital, and provides a buffer through cycles.
Emerging Markets Revenue Strength
Broad-based organic growth led by emerging markets (mid-single digits) and standout country performance (India double-digits) diversifies revenue sources. Geographic breadth reduces dependence on any single economy and supports more stable long-term top-line growth.
Hill's Premium Pet Franchise
Hill's operates as a premium, higher-margin franchise with therapeutic and wet segments growing and e-commerce momentum. Its pricing power, clinical positioning and category mix offer durable structural tailwinds and a stable profit contributor over time.
People also ask
What is the 12-month price target for Colgate-Palmolive (CL)?
tipranks publishes an average 12-month price target of 98.33 (Potential Growth = 5.62%), as read on 2026-10-27. The highest target is USD 106 and the lowest is USD 87. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.
How many analysts cover Colgate-Palmolive (CL)?
tipranks records 12 analyst ratings: 8 buy, 4 hold and 0 sell, which it summarises as “Moderate Buy”, as read on 2026-10-27.
What is the tipranks score for Colgate-Palmolive (CL)?
tipranks scores it 7 out of 10 and calls that “Neutral”, as read on 2026-10-27. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.
Is this CariBroker’s own forecast for Colgate-Palmolive?
No. Every figure on this page is published by tipranks, copied on 2026-10-27 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
Disclaimer
CariBroker provides information only and does not provide investment, financial or legal advice.
Check another company
Search every bank, broker and alert list in one place
